We believe that substitution of the MEK inhibitor, which suppresses ERK signaling in normal and tumor cells and has a narrow therapeutic index, with a mutant-selective RAS inhibitor and the use of a mTORC1-selective kinase inhibitor, may allow the safe administration of this combination in humans. The gene discussed is MAP2K7; the disease is neoplasm.